+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for PNH Market - Global Forecast 2026-2032- Product Image
Drugs for PNH Market - Global Forecast 2026-2032- Product Image
Sale

Drugs for PNH Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117908
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drugs for PNH Market is projected to reach USD 2.06 Billion in 2026. It is expected to continue growing at a CAGR of 9.02%, reaching USD 3.51 Billion by 2032.

Drugs for PNH: Executive Summary and Strategic Context

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder caused by somatic mutations affecting glycosylphosphatidylinositol-anchored proteins, leaving blood cells vulnerable to complement-mediated destruction. Drug development and clinical practice center on controlling hemolysis, reducing thrombosis risk, managing anemia, and improving quality of life. Treatment selection depends on disease activity, transfusion requirements, renal function, thrombotic history, pregnancy considerations, administration preferences, and access to specialist care.

Treatment Is Shifting Toward More Convenient and Durable Complement Control

The therapeutic landscape is moving beyond the initial focus on terminal complement inhibition toward differentiated approaches that may address extravascular hemolysis, dosing burden, and incomplete control of anemia. Long-acting administration, oral options, proximal complement targeting, and individualized switching strategies are reshaping treatment discussions. Persistent priorities include vaccination and infection-risk management, monitoring for breakthrough hemolysis, adherence support, and coordinated care across hematology, nephrology, and thrombosis services.

Artificial Intelligence Can Strengthen PNH Diagnosis, Monitoring, and Drug Development

Artificial intelligence can help identify unusual combinations of hemolysis, cytopenias, thrombosis, and renal abnormalities that warrant flow-cytometric evaluation, although it cannot replace specialist diagnosis. In clinical practice, machine-learning tools may support longitudinal analysis of lactate dehydrogenase, hemoglobin, reticulocyte counts, transfusions, symptoms, and breakthrough events. In research, AI can improve patient identification, trial matching, safety-signal detection, imaging and laboratory data integration, and prediction of treatment response, provided that rare-disease datasets are sufficiently validated, representative, and privacy protected.

Regional Insights: Access, Diagnosis, and Administration Capacity Define Treatment Pathways

North America generally benefits from specialized hematology networks and established complement-inhibitor experience, while affordability, prior authorization, and site-of-care logistics remain important considerations. Europe combines strong rare-disease infrastructure with country-level variation in reimbursement, referral pathways, and home-administration availability. Asia-Pacific contains advanced treatment centers alongside substantial gaps in recognition, testing, and access across lower-resource settings. Latin America faces uneven specialist coverage, diagnostic delays, and procurement constraints. The Middle East is developing rare-disease capabilities, with access concentrated in major centers. Africa continues to face limited awareness, flow-cytometry capacity, and availability of specialized therapies, making diagnosis and referral infrastructure central priorities.

Group Insights: Economic and Alliance Structures Shape Policy Coordination

ASEAN members differ substantially in diagnostic infrastructure, reimbursement, and specialist availability, encouraging regional collaboration on referral pathways and procurement. BRICS economies combine significant clinical capacity with wide internal disparities in access, requiring locally appropriate financing and diagnostics strategies. The European Union benefits from cross-border rare-disease networks, while national health-technology assessment and reimbursement decisions remain decisive. G7 systems generally have mature specialist services but continue to address affordability, equitable access, and treatment administration. GCC countries are strengthening centralized specialty care and genomic services, with referral coordination remaining important. NATO members span diverse health systems, so alliance membership does not imply uniform PNH access or treatment policy.

Country Insights: National Health Systems Create Distinct PNH Priorities

Australia and Canada must balance geographically dispersed specialist services with timely diagnosis and treatment access. Brazil, Mexico, India, China, and Russia face substantial regional variation in referral capacity, laboratory availability, and reimbursement, despite major tertiary-care expertise. France, Germany, Italy, Spain, and the United Kingdom have established rare-disease and hematology pathways, but coverage rules, commissioning, and site-of-care models differ. Japan and South Korea combine advanced clinical capabilities with structured reimbursement environments and aging-population considerations. In the United States, specialist access and treatment choice are comparatively broad, while insurance authorization, infusion logistics, and affordability remain practical barriers.

Action Priorities for Leaders: Improve Diagnosis, Personalize Therapy, and Protect Continuity

Industry leaders should strengthen partnerships with hematology centers to shorten diagnostic delays and expand access to high-quality flow cytometry. Treatment strategies should be aligned with hemolysis control, anemia burden, thrombosis history, renal outcomes, patient preferences, and administration feasibility rather than relying on a single pathway. Evidence generation should include real-world outcomes, patient-reported measures, breakthrough-hemolysis characterization, pregnancy data where appropriate, and comparative treatment sequencing. Patient-support programs should emphasize vaccination, infection awareness, adherence, travel planning, and rapid evaluation of symptoms. Regional access plans should account for reimbursement, cold-chain and infusion requirements, home-care infrastructure, and the needs of underserved populations.

Research Methodology: Evidence Triangulation for a Rare Hematologic Disorder

This executive summary is based on established clinical and public-health knowledge concerning PNH biology, complement-mediated hemolysis, diagnostic practice, treatment objectives, and health-system access. The assessment synthesizes peer-reviewed literature, regulatory and clinical guidance, rare-disease network principles, and documented healthcare-system characteristics. Regional, group, and country observations are presented qualitatively and avoid unsupported numerical claims. Interpretation should be updated as guidelines, approved therapies, reimbursement policies, safety evidence, and diagnostic capabilities evolve.

Conclusion: Sustainable PNH Care Requires Integrated Clinical and Access Strategies

PNH management is becoming more individualized as complement biology, treatment formats, and monitoring capabilities advance. The strongest outcomes depend not only on selecting an effective drug, but also on prompt diagnosis, vaccination and safety planning, reliable laboratory follow-up, thrombosis prevention, renal protection, and coordinated specialist care. Leaders who combine evidence-based therapy with practical access solutions and responsible use of digital tools will be better positioned to address the diverse needs of people living with PNH.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drugs for PNH Market, by Drug Class
7.1. Introduction
7.2. Proximal Complement Inhibitors
7.3. Terminal Complement Inhibitors
7.3.1. Eculizumab
7.3.2. Ravulizumab
8. Drugs for PNH Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Subcutaneous
9. Drugs for PNH Market, by Distribution Channel
9.1. Introduction
9.2. Home Infusion
9.3. Hospital Pharmacy
9.4. Specialty Pharmacy
10. Drugs for PNH Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Care
10.4. Hospitals
11. Drugs for PNH Market, by Line Of Therapy
11.1. Introduction
11.2. First-Line
11.3. Subsequent-Line
12. Drugs for PNH Market, by Age Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
12.4. Geriatric
13. Drugs for PNH Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Drugs for PNH Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Drugs for PNH Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Alexion Pharmaceuticals, Inc.
17.3. Amgen Inc.
17.4. Apellis Pharmaceuticals, Inc.
17.5. AstraZeneca PLC
17.6. Biogen Inc.
17.7. Boehringer Ingelheim International GmbH
17.8. Bristol Myers Squibb Company
17.9. Catalyst Biosciences, Inc.
17.10. Ionis Pharmaceuticals, Inc.
17.11. Janssen Pharmaceuticals, Inc.
17.12. Merck & Co., Inc.
17.13. Novartis AG
17.14. Pfizer Inc.
17.15. Ra Pharmaceuticals
17.16. Regeneron Pharmaceuticals, Inc.
17.17. Roche Holding AG
17.18. Sanofi
17.19. Swedish Orphan Biovitrum AB
17.20. UCB S.A.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Drugs for PNH Market, Years Considered for the Study
FIGURE 2. Global Drugs for PNH Market, Research Design
FIGURE 3. Global Drugs for PNH Market, Research Framework
FIGURE 4. Global Drugs for PNH Market, Data Triangulation
FIGURE 5. Global Drugs for PNH Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Drugs for PNH Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Drugs for PNH Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Drugs for PNH Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Drugs for PNH Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Drugs for PNH Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Drugs for PNH Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Drugs for PNH Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Drugs for PNH Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Drugs for PNH Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 15. Global Drugs for PNH Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Drugs for PNH Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 17. Global Drugs for PNH Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Drugs for PNH Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Drugs for PNH Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Drugs for PNH Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Drugs for PNH Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Drugs for PNH Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Drugs for PNH Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Drugs for PNH Market Segmentation & Coverage
TABLE 2. Global Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 3. Global Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Proximal Complement Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Proximal Complement Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Proximal Complement Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Terminal Complement Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Terminal Complement Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Terminal Complement Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Eculizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ravulizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ravulizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ravulizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 17. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 24. Global Home Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Home Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Home Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 34. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 44. Global First-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global First-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global First-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Subsequent-Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Subsequent-Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Subsequent-Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 51. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Drugs for PNH Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Drugs for PNH Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 69. North America Drugs for PNH Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. North America Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 71. North America Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 72. North America Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 73. North America Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. North America Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. North America Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 76. North America Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 77. Latin America Drugs for PNH Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Latin America Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 79. Latin America Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 80. Latin America Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 81. Latin America Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Latin America Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 83. Latin America Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 84. Latin America Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 85. Europe Drugs for PNH Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Europe Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 87. Europe Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 88. Europe Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 89. Europe Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. Europe Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Europe Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 92. Europe Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 93. Middle East Drugs for PNH Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Middle East Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 95. Middle East Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 96. Middle East Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 97. Middle East Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Middle East Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Middle East Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 100. Middle East Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 101. Africa Drugs for PNH Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Africa Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 103. Africa Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 104. Africa Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 105. Africa Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. Africa Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Africa Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 108. Africa Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 109. Global Drugs for PNH Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. ASEAN Drugs for PNH Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. ASEAN Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 112. ASEAN Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 113. ASEAN Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 114. ASEAN Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 115. ASEAN Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. ASEAN Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 117. ASEAN Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 118. GCC Drugs for PNH Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. GCC Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 120. GCC Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 121. GCC Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 122. GCC Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. GCC Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. GCC Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 125. GCC Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 126. European Union Drugs for PNH Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. European Union Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 128. European Union Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 129. European Union Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 130. European Union Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. European Union Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. European Union Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 133. European Union Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 134. BRICS Drugs for PNH Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. BRICS Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 136. BRICS Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 137. BRICS Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 138. BRICS Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. BRICS Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. BRICS Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 141. BRICS Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 142. G7 Drugs for PNH Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. G7 Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 144. G7 Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 145. G7 Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. G7 Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. G7 Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. G7 Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 149. G7 Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 150. NATO Drugs for PNH Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. NATO Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 152. NATO Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 153. NATO Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 154. NATO Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. NATO Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. NATO Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 157. NATO Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 158. Global Drugs for PNH Market Size, by Country, 2017-2032 (USD Million)
TABLE 159. United States Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 160. United States Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 161. United States Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 162. United States Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 163. United States Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. United States Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. United States Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 166. United States Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 167. Canada Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 168. Canada Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 169. Canada Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 170. Canada Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. Canada Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. Canada Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Canada Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 174. Canada Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 175. Mexico Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 176. Mexico Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 177. Mexico Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 178. Mexico Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 179. Mexico Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. Mexico Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Mexico Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 182. Mexico Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 183. Brazil Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 184. Brazil Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 185. Brazil Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 186. Brazil Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 187. Brazil Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Brazil Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. Brazil Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 190. Brazil Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 191. United Kingdom Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 192. United Kingdom Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 193. United Kingdom Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 194. United Kingdom Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 195. United Kingdom Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. United Kingdom Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. United Kingdom Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 198. United Kingdom Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 199. Germany Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 200. Germany Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 201. Germany Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 202. Germany Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 203. Germany Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Germany Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Germany Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 206. Germany Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 207. France Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 208. France Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 209. France Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 210. France Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 211. France Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. France Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. France Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 214. France Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 215. Russia Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 216. Russia Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 217. Russia Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 218. Russia Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 219. Russia Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. Russia Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. Russia Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 222. Russia Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 223. Italy Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 224. Italy Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 225. Italy Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 226. Italy Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 227. Italy Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. Italy Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Italy Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 230. Italy Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 231. Spain Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 232. Spain Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 233. Spain Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 234. Spain Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 235. Spain Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Spain Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Spain Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 238. Spain Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 239. China Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 240. China Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 241. China Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 242. China Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. China Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. China Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. China Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 246. China Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 247. India Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 248. India Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 249. India Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 250. India Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 251. India Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. India Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. India Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 254. India Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 255. Japan Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 256. Japan Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 257. Japan Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 258. Japan Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 259. Japan Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 260. Japan Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. Japan Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 262. Japan Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 263. Australia Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 264. Australia Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 265. Australia Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 266. Australia Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 267. Australia Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. Australia Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. Australia Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 270. Australia Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 271. South Korea Drugs for PNH Market Size, 2017-2032 (USD Million)
TABLE 272. South Korea Drugs for PNH Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 273. South Korea Drugs for PNH Market Size, by Terminal Complement Inhibitors, 2017-2032 (USD Million)
TABLE 274. South Korea Drugs for PNH Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 275. South Korea Drugs for PNH Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 276. South Korea Drugs for PNH Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. South Korea Drugs for PNH Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 278. South Korea Drugs for PNH Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 279. Global Drugs for PNH Market Share, by Key Player, 2025
TABLE 280. Global Drugs for PNH Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Ra Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Swedish Orphan Biovitrum AB
  • UCB S.A.

Related Topics

Related Reports

RNA Therapies - Competitive Landscape, 2026 - Product Image

RNA Therapies - Competitive Landscape, 2026

  • Report
  • 280 Pages
  • Global
From
Veopoz Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Veopoz Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Geographic Atrophy Drugs Market - Global Forecast 2026-2032 - Product Image

Geographic Atrophy Drugs Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Gout Medications Market - Global Forecast 2026-2032 - Product Image

Gout Medications Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Medical Foods for Orphan Diseases - Global Strategic Business Report - Product Image

Medical Foods for Orphan Diseases - Global Strategic Business Report

  • Report
  • 374 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.